Pain affects over half of patients with advanced pancreatic cancer

This nationwide cohort study (PACAP-PROM registry, 2016-2023) assessed pain prevalence in 794 patients with locally advanced or metastatic pancreatic cancer using EORTC QLQ-C30, PAN26, and EQ-5D-5L measures. At baseline, 54% to 78% of patients reported pain, with no difference between locally advanced and metastatic disease; patients receiving best supportive care reported more pain and greater pain-related interference than those receiving chemotherapy, and chemotherapy was independently associated with lower odds of higher pain severity and interference. The study authors state these findings underscore the need for routine pain assessment and individualized symptom management from diagnosis onward.

Most relevant for: Patients with locally advanced or metastatic pancreatic cancer, including those managed with chemotherapy or best supportive care.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.